In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Clinical Trials (PDQ®)

Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IVSupportive careActive18 and overOtherMann-Cohen Version 2
NCT01459666

Trial Description

Summary

Evaluate the efficacy and safety of using aboBTX-A to improve wound healing prior to Mohs micrographic surgery and reconstruction for skin cancer of the forehead

Further Study Information

  • Outcomes by the Patient and Observer Assessment Scale (POSAS), Visual Analog Scale, and Patient Satisfaction Survey.
  • Study consists of 5 clinic visits over approximately 6 months

Eligibility Criteria

Inclusion Criteria:

  • Have biopsy proven skin cancer on the forehead that is amenable to Mohs surgery
  • Undergoing elective reconstruction of biopsy proven skin cancer that is amenable to Mohs surgery with defect size measuring 1.0 cm or greater
  • If female, not currently pregnant, not currently breastfeeding, no potential for pregnancy, or if of child-bearing age, agrees to using birth control.
  • Agrees to not use disallowed concomitant medications (retinoids) and agrees to use sunscreen in the forehead area for the duration of the study

Exclusion Criteria:

  • Current or past history of a neuromuscular disease (such as myasthenia gravis, amyotrophic lateral sclerosis, Eaton-Lambert syndrome)
  • History of radiation therapy or chemotherapy
  • History of keloid or other hypertrophic scar formation
  • Has used botulinum toxin in the forehead area within one year.
  • Has used any topical retinoids to the forehead area within the past 4 weeks
  • Any hypersensitivity to any component of abobotulinumtoxinA (i.e. cow milk protein) or any previous hypersensitivity to any botulinum toxin A or related product.

Trial Contact Information

Trial Lead Organizations/Sponsors

AboutSkin Dermatology and DermSurgery, PC

Case Comprehensive Cancer Center

Medicis Pharmaceutical Corporation

Margaret Mann, MDPrincipal Investigator

Joel L Cohen, MDPrincipal Investigator

Jessica SussmanPh: 303-756-7546
  Email: research@aboutskinderm.com

Trial Sites

U.S.A.
Colorado
  Englewood
 AboutSkin Dermatology and DermSurgery, PC
 Jessica Sussman Ph: 303-756-7546
  Email: research@aboutskinderm.com
 Joel L Cohen, MDPrincipal Investigator
Ohio
  Cleveland
 Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
 Kristen Doud, CCRP Ph: 216-983-0861
  Email: kristen.doud@uhhospitals.org
 Margaret Mann, MDPrincipal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01459666
ClinicalTrials.gov processed this data on October 10, 2014

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top